Se connecter

Bibliographies thématiques / Interleukin-6

Sommaire

Articles de revues
Thèses
Livres
Chapitres de livres
Actes de conférences
Rapports d'organisations

Littérature scientifique sur le sujet « Interleukin-6 »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 9 juin 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Interleukin-6 ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Interleukin-6"

1

&NA;. "Interleukin-3/interleukin-6." Reactions Weekly &NA;, no. 550 (May 1995): 11. http://dx.doi.org/10.2165/00128415-199505500-00035.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

&NA;. "Interleukin-6." Reactions Weekly &NA;, no. 570 (September 1995): 9. http://dx.doi.org/10.2165/00128415-199505700-00023.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Lotz, Martin. "Interleukin-6." Cancer Investigation 11, no. 6 (January 1993): 732–42. http://dx.doi.org/10.3109/07357909309046948.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

&NA;. "Interleukin 6." Inpharma Weekly &NA;, no. 877 (March 1993): 2. http://dx.doi.org/10.2165/00128413-199308770-00001.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

&NA;. "Interleukin 6." Reactions Weekly &NA;, no. 505 (June 1994): 8. http://dx.doi.org/10.2165/00128415-199405050-00037.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

&NA;. "Interleukin 6." Reactions Weekly &NA;, no. 531 (December 1994): 8. http://dx.doi.org/10.2165/00128415-199405310-00027.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Song, Mingchen, and John A. Kellum. "Interleukin-6." Critical Care Medicine 33, Suppl (December 2005): S463—S465. http://dx.doi.org/10.1097/01.ccm.0000186784.62662.a1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

CASTELL, JOSé V., TILO ANDUS, DIETER KUNZ, and PETER C. HEINRICH. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 87–101. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24001.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

LEE, FRANK, CHOY-PIK CHIU, JANUSZ WIDEMAN, PHILLIP HODGKIN, SUSAN HUDAK, LOUISE TROUTT, THERESA NG, et al. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 215–29. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24015.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

CLARK, STEVEN C. "Interleukin-6." Annals of the New York Academy of Sciences 557, no. 1 (June 28, 2008): 438–43. http://dx.doi.org/10.1111/j.1749-6632.1989.tb24036.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Interleukin-6"

1

Schebesta, Kathrin [Verfasser]. "Das Endothel sezerniert Interleukin-6 (IL-6) und stimuliert die adrenale Interleukin-6 und Aldosteronsynthese über einen Interleukin-6 unabhängigen Mechanismus / Kathrin Schebesta." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2015. http://d-nb.info/1079652612/34.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

OBAFEMI, TOLULOPE FESAYO. "THE EFFECTS OF INTERLEUKIN 6 AND INTERLEUKIN 10 ON FRAILTY IN C57BL/6 MICE." Thesis, The University of Arizona, 2016. http://hdl.handle.net/10150/613394.

Texte intégral

Résumé :

Studies have shown that pro-inflammatory IL-6 and anti-inflammatory IL-10 interleukins may correlate to frailty and aging. This frailty can be defined in the context of clinical symptoms which include sarcopenia and osteoporosis, decreased activity level; or in the context of increased susceptibility to adverse health outcomes from a deficient immune system. In this experiment we tested a cohort of conditionally regulated IL-6 and IL-10 mice with controls (IL-6tg+.rtTA(r/r) (n=8), IL-10(-/-). IL-10tg+ rtTA(r/r) (n=10) and rtTA(r/r) (n=5)) under frailty assessments and immunological cell analysis. We were unable to successfully induce expression in the conditionally regulated mice. Subsequently, there was no difference in the frailty scores, weight, or temperature fluctuation between all three genotypes. As a preliminary study, there arose essential learning points of improvement that can be applied to future experiments concerning frailty in transgenic mice.

Styles APA, Harvard, Vancouver, ISO, etc.

3

Terry, Catherine. "Genetic control of Interleukin-6 gene." Thesis, University of Oxford, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.342452.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Höschen-Lihs, Jutta. "Interleukin-6- und Interleukin-2-Rezeptor als Aktivitätsmarker bei infektiöser Endokarditis." [S.l.] : [s.n.], 2005. http://archiv.ub.uni-marburg.de/diss/z2005/0327/.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Siegmund, Annette. "Interleukin-11 - analog zu Interleukin-6 - ein direkter Modulator der Nebennierenrinde." Diss., lmu, 2008. http://nbn-resolving.de/urn:nbn:de:bvb:19-83542.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Desallais, Lucille. "Immunisation active à base de peptides, dérivés de l’IL-6 et de l’IL-1β, dans les maladies inflammatoires chroniques". Thesis, Paris, CNAM, 2013. http://www.theses.fr/2013CNAM0867.

Texte intégral

Résumé :

Les anticorps monoclonaux anti-cytokine ont constitué une révolution dans le traitement des maladies inflammatoires chroniques, mais leur utilisation présente des inconvénients (non réponse, résistance, effets secondaires, coûts élevés).Notre équipe développe une stratégie alternative originale, l’immunisation active à base de peptides de cytokines. Elle a pour but de faire synthétiser, par l’organisme même du patient, des anticorps neutralisant les effets pathogènes dus à l’excès de cytokines.Durant ma thèse, j’ai montré que l’immunisation active contre un peptide dérivé de l’IL-6 murine est protectrice dans un modèle murin de sclérodermie systémique. L’immunisation de singes avec l’équivalent humain entraîne une réduction significative des réactions inflammatoires locales suite à l’induction d’une réaction d’HSR. De plus, l’immunisation active contre deux peptides dérivés de l’IL-1β et de l’IL-23 conduit à la réduction de la sévérité de l’EAE.Ces résultats confortent l’intérêt de cibler les cytokines par l’approche d’immunisation active à base de peptides, qui pourra permettre de diversifier l’offre thérapeutique actuellement disponible<br>Monoclonal antibodies have been a revolution for the treatment of chronic inflammatory diseases, but their use shows major drawbacks (non-response, resistance, side effects and prohibitive costs).Our team develops an original alternative strategy: anti-cytokine peptide-based active immunization.The aim of the approach is to make the patient’s own organism produce antibodies capable of neutralizing the pathogenic effects of cytokine overproduction.During my PhD, I have demonstrated that active immunization against an IL-6 murine peptide confers clinical protection in a murine model of systemic sclerosis. Monkeys immunized against the human peptide also showed a significant decrease of local inflammatory reactions following a delayed-type hypersensitivity reaction. Moreover, active immunization against an IL-1β and an IL-23 murinepeptide led to a reduction of the severity of the EAE in mice.These results comfort the interest of anti-cytokine peptide-based active immunization, which should eventually widen the choice of therapeutics available for the patients

Styles APA, Harvard, Vancouver, ISO, etc.

7

Walter, Claudia. "Bestimmung der Zytokine Interleukin-1ra, Interleukin-6, Interleukin-10 und Interleukin-12 im Vaginalsekret bei Frauen mit Bakterieller Vaginose." Diss., lmu, 2004. http://nbn-resolving.de/urn:nbn:de:bvb:19-28461.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Slawik, Helen Christina. "Kontinuierliche Überexpression von Interleukin-6 im Zentralnervensystem lokale Applikation des Designerzytokins Hyper-Interleukin-6 im adulten Organismus der Ratte und Auswirkungen von exzitatorischen Neurotoxinen im Interleukin-6-transgenen Mausmodell /." [S.l.] : [s.n.], 2003. http://www.freidok.uni-freiburg.de/volltexte/842.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Gopinathan, Ganga. "The effects of interleukin-6 on angiogenesis." Thesis, Queen Mary, University of London, 2014. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8186.

Texte intégral

Résumé :

Elevated levels of the inflammatory cytokine interleukin-6, IL-6, have been linked with poor prognosis in ovarian cancer patients by influencing tumour growth, invasion, angiogenesis and chemo-resistance. A clinical trial conducted in parallel with pre-clinical studies showed an anti-IL-6 antibody to have some activity in ovarian cancer patients and in xenograft models, via reduction in pro-inflammatory and angiogenic factors such as TNF-α, IL-8 and VEGF. Anti-IL-6 treatment also showed significant reductions in vascular area with decreased expression of an angiogenic factor Jagged1. The aim of my study was to investigate the effects of IL-6 on normal and tumour angiogenesis. I found that recombinant IL-6 stimulates angiogenesis in mouse and rat aortic ring assays and that it can also stimulate growth and migration of endothelial cells in vitro. IL-6 has similar potency as VEGF in inducing vessel sprouting. IL-6 itself does not induce VEGF in the endothelial cells I tested. Investigation of the effects of IL-6 on vessel maturation revealed a significant reduction in pericyte coverage of vessels treated with IL-6 compared with VEGF. Collectively, these data led to my hypothesis that ‘IL-6 drives aberrant angiogenesis, independent of VEGF signalling’. Investigating the mechanism by which IL-6 drives angiogenesis and leads to defective pericyte formation, I showed a link between IL-6 and the Notch ligands, Jagged1 and DLL4. My data suggested that IL-6 could stimulate Jagged1 in endothelial cells, whereas VEGF induces DLL4, the Notch ligand known to be involved in inducing stalk phenotype. Exploring previous findings to get a better understanding of the interaction of Notch ligands and pericyte recruitment also suggested a role of Angiopoeitin-2 in relation to IL-6 signalling. These observations were extended in IGROV-1 ovarian cancer xenografts treated with an anti-IL-6 antibody and by analysis of gene expression datasets from ovarian cancer biopsies. My results suggest therapeutic potential of combining inhibitors of IL-6 and VEGF in ovarian cancer.

Styles APA, Harvard, Vancouver, ISO, etc.

10

Sonnenberg, Sabine. "Tissue specific genetic regulation of Interleukin 6." Thesis, University of Southampton, 2009. https://eprints.soton.ac.uk/72590/.

Texte intégral

Résumé :

Interleukin 6 (IL6) is associated with arterial disease development, progression and surgical outcome. Raised levels of IL6 may play a causal role in disease development or may be the effect of pathology. An IL6 single nucleotide polymorphism (SNP) G- 174C has been identified and reported to associate with IL6 expression. However, conflicting results have emerged and both the relationship between IL6 and vascular disease and the precise effect of SNP G-174C in vivo in humans remains obscure. The aim of this study was to establish the effect of SNP G-174C in humans, in vivo in different tissues. Varicose vein surgery patients donated adipose tissue, skeletal muscle, vein and blood samples. Patients were genotyped for SNP G-174C. A new pre-mRNA assay was developed, using gel electrophoresis, restriction digest and fluorescence quantification, to measure the ratio of heterozygous allelic pre-mRNA transcription. IL6 mRNA expression in different tissues was also measured using relative real time PCR (RT-PCR) to assess effect of tissue type on expression profiles. mRNA expression within tissues was compared between G-174C genotypes, to further quantifying the association of SNP G-174C with transcript levels. The pre-mRNA assay showed higher expression for the C-allele, though not statistically significant. The pre-mRNA assay needed to detect low levels of intron retaining allelic pre-mRNA isoforms. Replicates and controls for residual genomic DNA were used to monitor assay precision. Adipose tissue gave the greatest precision in the pre-mRNA assay. In the RT PCR assay adipose tissue expressed significantly more IL6 mRNA than all other tissues examined. In vein and leukocytes subjects with the CC genotype expressed significantly higher levels of IL6 mRNA than subjects with GC or GG genotypes. There was a trend towards higher expression for the CC genotype in all tissue types. A significant though weak correlation between IL6 mRNA expression and age was demonstrated for vein and leukocytes. Adipose tissue may be an important source of IL6 compared to other tissues. This may be relevant for obesity associated diseases. Subjects with G-174C genotype CC showed a trend towards higher IL6 RNA expression. Further studies are necessary to clarify the effect of genotype on IL6 expression.

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Livres sur le sujet "Interleukin-6"

1

Andrzej, Mackiewicz, Koj A, and Sehgal Pravinkumar B, eds. Interleukin-6-type cytokines. New York: New York Academy of Sciences, 1995.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Tamas, Bartfai, and Ottoson David 1918-, eds. Neuro-immunology of fever. Oxford [England]: Pergamon Press, 1992.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Paulwitz, Adelheid. Diagnostische Wertigkeit von Interleukin-1, Interleukin-6, Interleukin-8, TNF-[alpha] [TNF-alpha] und PMN-Elastase bei akuter Pankreatitis. [s.l.]: [s.n.], 1998.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Young, Rosemary Irene. Cytokines and cancer: A focus on Interleukin-6. Manchester: University of Manchester, 1994.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

B, Sehgal Pravinkumar, Grieninger Gerd, Tosato Giovanna, New York Academy of Sciences., and National Foundation for Cancer Research., eds. Regulation of the acute phase and immune responses: Interleukin-6. New York, N.Y: New York Academy of Sciences, 1989.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Schwarze, Melinda Margarete K. Mechanisms of prevention of apoptosis in an interleukin-6-dependent myeloma cell line. Ottawa: National Library of Canada, 1995.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Moldoveanu, Andrei Ion. Effects of prolonged endurance exercise on the gene expression and plasma levels of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha. Ottawa: National Library of Canada, 1999.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Rindermann, Dominik. Serumbestimmung von TPS, [beta]2-Mikroglobulin, G-CSF und Interleukin-6 bei Patienten mit metastasierten Nierenzellkarzinom während überwiegend lokaler Immuntherapie mit Interleukin-2. [s.l.]: [s.n.], 1998.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Cournoyer, Micheline. Circulating endotoxin, interleukin-6 and tumor necrosis factor alpha in a porcine model of intraabdominal sepsis. Ottawa: National Library of Canada, 1995.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

1946-, Kluger Matthew J., Oppenheim Joost J. 1934-, and Powanda M. C, eds. The Physiologic, metabolic, and immunologic actions of interleukin-1: Proceedings of a symposium held in Ann Arbor, Michigan, June 4-6, 1985. New York: Liss, 1985.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Chapitres de livres sur le sujet "Interleukin-6"

1

Hirano, T., and T. Kishimoto. "Interleukin-6." In Peptide Growth Factors and Their Receptors I, 633–65. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-49295-2_14.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Van Snick, J., and R. P. Nordan. "Interleukin 6." In Growth Factors, Differentiation Factors, and Cytokines, 163–76. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74856-1_12.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Chen, Taosheng. "Interleukin-6." In Encyclopedia of Cancer, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_3099-3.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Tanaka, Toshio, Masashi Narazaki, and Tadamitsu Kishimoto. "Interleukin-6." In Encyclopedia of Medical Immunology, 579–87. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-0-387-84828-0_38.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Gressner, A. M., and O. A. Gressner. "Interleukin-6." In Lexikon der Medizinischen Laboratoriumsdiagnostik, 1–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_1597-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Gressner, A. M., and O. A. Gressner. "Interleukin-6." In Springer Reference Medizin, 1265–66. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_1597.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Kishimoto, Tadamitsu, and Toshio Tanaka. "Interleukin 6." In Compendium of Inflammatory Diseases, 686–92. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_179.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Hirano, T., and T. Kishimoto. "Interleukin-6." In Peptide Growth Factors and Their Receptors I, 633–65. New York, NY: Springer New York, 1991. http://dx.doi.org/10.1007/978-1-4612-3210-0_14.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Chen, Taosheng. "Interleukin-6." In Encyclopedia of Cancer, 2317–19. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_3099.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Chen, Taosheng. "Interleukin-6." In Encyclopedia of Cancer, 1895–96. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_3099.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Interleukin-6"

1

Morales, Jennifer M., Justin R. Bickford, Sanchao Liu, Alexander Winton, Matthew Coppock, Pak Cho, and Paul M. Pellegrino. "Photonic Integrated Circuits with Protein Catalyzed Capture Agents for Biosensing in Complex Media." In Optical Sensors, STu1H.3. Washington, D.C.: Optica Publishing Group, 2024. https://doi.org/10.1364/sensors.2024.stu1h.3.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Hu, X., and R. Xing. "Effect of Alternating Electric Field on the Conformation and Function of Interleukin-6." In 2024 IEEE International Conference on Plasma Science (ICOPS), 1. IEEE, 2024. http://dx.doi.org/10.1109/icops58192.2024.10626532.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Jenkins, Brendan J., Louise McLeod, Alistair Miller, Jessica Jones, Steven Bozinovski, Ross Vlahos, Phillip Bardin, Gary P. Anderson, and Saleela Ruwanpura. "Interleukin-6 Promotes Emphysema By Apoptosis." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5800.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Gopinathan, Ganga, Carla Milagre, Oliver M. T. Pearce, Louise Reynolds, Kairbaan Hodivala-Dilke, Andrew Leinster, Haihong Zhong, et al. "Abstract 4162: Interleukin–6 stimulates defective angiogenesis." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4162.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Pereira da Silva, F., F. Luís, F. Jesus, É. Almeida, S. Braga, J. Ribeiro, R. Natal, J. Costa, M. Tavares, and L. Ferreira. "Interleukin-6 in SARS-CoV2 risk stratification." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.2216.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Perea, Beatrice, Miriana D’Alessandro, Laura Bergantini, Sara Gangi, Benedetta Zilio, Paolo Cameli, and Elena Bargagli. "Interleukin-6 and krebs von den lungen-6 in lymphangioleiomyomatosis patients." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa3949.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Wiegertjes, R., A. van Caam, H. van Beuningen, P. van der Kraan, F. van de Loo, and E. Blaney Davidson. "P078 Transforming growth factor-beta dampens pro-inflammatory interleukin-6 signaling in chondrocytes by decreasing the interleukin-6 receptor." In 39th European Workshop for Rheumatology Research, 28 February–2 March 2019, Lyon, France. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2018-ewrr2019.67.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Tadjibayeva, K., and T. R. Romanovskaya. "REGULATORY ROLE OF INTERLEUKINS-4, 5 AND 6 IN THE DEVELOPMENT OF GLOMERULONEPHRITIS OF VARIOUS ETIOLOGIES." In SAKHAROV READINGS 2022: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute of Belarusian State University, 2022. http://dx.doi.org/10.46646/sakh-2022-2-24-27.

Texte intégral

Résumé :

The relationship between the concentration of interleukin-4, 5, and 6 with the content of eosinophils and the level of C-reactive protein in patients with chronic glomerulonephritis was established. An increase in eosinophils was found in patients with chronic glomerulonephritis with a predominance of interleukin-4 compared with patients with a predominance of interleukin-5 and 6, which may be an important diagnostic marker of glomerulonephritis.

Styles APA, Harvard, Vancouver, ISO, etc.

9

Tsang, Andra, and Brian Oliver. "Budesonide reduced stone dust and cigarette smoke-induced interleukin 6 and interleukin 8 production." In ERS Congress 2024 abstracts, PA4894. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa4894.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Kura, Yurie, Marco A. De Velasco, Yasuyuki Kobayashi, Naomi Ando, Emiko Fukushima, Yutaka Yamamoto, Yuji Hatanaka, et al. "Abstract 1226: Interleukin-6 (IL-6) as a therapeutic target in prostate cancer." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1226.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Interleukin-6"

1

Keller, Evan T. Interleukin-6 and Prostate Cancer Progression. Fort Belvoir, VA: Defense Technical Information Center, July 2001. http://dx.doi.org/10.21236/ada398242.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Keller, Evan T. Interleukin-6 and Prostate Cancer Progression. Fort Belvoir, VA: Defense Technical Information Center, July 2002. http://dx.doi.org/10.21236/ada407280.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Keller, Evan T. Interleukin-6 and Prostate Cancer Progression. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada418080.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Rokita, Hanna, Ruta Neta, and Jean D. Sipe. Increased Fibrinogen Synthesis in Mice During the Acute Phase Response: Co-Operative Interaction of Interleukin 1, Interleukin 6, and Interleukin 1 Receptor Antagonist. Fort Belvoir, VA: Defense Technical Information Center, September 1993. http://dx.doi.org/10.21236/ada280464.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Knudsen, Beatrice S. Hepatocyte Growth Factor and Interleukin-6 in Prostate Cancer Bone Metastasis. Fort Belvoir, VA: Defense Technical Information Center, March 2005. http://dx.doi.org/10.21236/ada435856.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Knudsen, Beatrice S. Hepatocyte Growth Factor and Interleukin-6 in Prostate Cancer Bone Metastasis. Fort Belvoir, VA: Defense Technical Information Center, March 2004. http://dx.doi.org/10.21236/ada428439.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Knudesen, Beatrice S. Hepatocyte Growth Factor and Interleukin-6 in Prostate Cancer Bone Metastasis. Fort Belvoir, VA: Defense Technical Information Center, March 2003. http://dx.doi.org/10.21236/ada416620.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Knudsen, Beatrice S. Hepatocyte Growth Factor and Interleukin-6 in Prostate Cancer Bone Metastasis. Fort Belvoir, VA: Defense Technical Information Center, June 2006. http://dx.doi.org/10.21236/ada467982.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Huang, Xinyi, Manman Zhang, Jiaojiao Wang, and Fuyong Hu. Association between interleukin-6 levels and stroke：a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2024. http://dx.doi.org/10.37766/inplasy2024.5.0089.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

กาญจนทัต, อภิชาติ. ความเป็นพิษและการเหนี่ยวนำการตายแบบอะโพโทซิสต่อเซลล์มะเร็ง โดยเพปไทด์จากเกสรผึ้งพันธุ์ Apis mellifera. สถาบันวิจัยเทคโนโลยีชีวภาพและวิศวกรรมพันธุศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย, 2018. https://doi.org/10.58837/chula.res.2018.100.

Texte intégral

Résumé :

งานวิจัยนี้เตรียมโปรตีนไฮโดรไลเสตจากเกสรผึ้งพันธุ์ ที่ได้จากปฏิกิริยาย่อยสลายด้วยเอนไซม์ 3 ชนิด ได้แก่ แอลคาเลส ฟลาโวไซม์ และนิวเทรส พบว่าเมื่อใช้นิวเทรสในอัตราส่วนของเอนไซม์ต่อสับสเตรต 1:1 (NH1) โดยปริมาตร จะให้แสดงค่าการยับยั้งการสร้างอนุมูลอิสระด้วยวิธีไนตริกออกไซต์ได้ดีที่สุด คัดแยกเพปไทด์ที่มีขนาดโมเลกุลต่ำกว่า 0.65 กิโลดาลตัน (MW1) มีฤทธิ์ในการขจัดอนุมูลอิสระไนตริกออกไซด์ได้ดีที่สุด จากนั่นได้ทำการตรวจสอบความเป็นพิษของ MW1 ด้วยวิธี MTT และตรวจสอบ ผลการยับยั้งการสร้างไนตริกออกไซด์ในเซลล์แมคโครฟาจ RAW 264.7 ที่ถูกกระตุ้นด้วยไลโปโพลิแซคคาไรด์ พบว่า MW1 ไม่มีความเป็นพิษต่อเซลล์ และมีฤทธิ์ในการยับยั้งการสร้างไนตริกออกไซด์ ผลการแสดงออกของยีนที่เกี่ยวของกับการอักเสบ พบว่า MW1 มีฤทธิ์ในการยับยั้งการแสดงออกของยีน inducible nitric oxide synthase (iNOS) Cyclooxygenase-2 (COX-2) Interleukin-6 (IL-6) และ Tumor necrosis factor alpha (TNF-α) จากนั้นนำ MW1 ไปทำบริสุทธิ์ด้วยเทคนิคโครมาโตกราฟีของเหลวสมรรถนะสูง สามารถแยกเพปไทด์ได้ทั้งหมด 6 พีค (H1-6) โดยที่ H2, H3 และ H4 แสดงค่าการยับยั้งการสร้างอนุมูลอิสระด้วยวิธีไนตริกออกไซด์ได้ดีที่สุด และนำเพปไทด์ที่ได้ไปพิสูจน์เอกลักษณ์ด้วยเทคนิคแมสสเปกโตรเมตรีพบเพปไทด์ทั้งหมด 7 สาย จากผลการศึกษาดังกล่าวแสดงให้เห็นว่าฤทธิ์ต้านการอักเสบของเพปไทด์จากเกสรผึ้งพันธุ์ สามารถนำไปประยุกต์ใช้ในอุสาหกรรมทางการแพทย์ เภสัชกรรมและผลิตภัณฑ์เครื่องสำอางต่อไป

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!